Current medical research and opinion · 2026
Real-world adherence to multi-target stool DNA testing and its association with time to follow-up colonoscopy: a health-system analysis from Massachusetts General Hospital.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Greene Mallik, Camardo Mark, Karlitz Jordan J, Nowd Peter, Wang Wei, Anderson Joseph, Kisiel John, Ebner Derek
Аннотация
INTRODUCTION: Multi-target stool DNA (mt-sDNA) testing is a noninvasive colorectal cancer (CRC) screening test with higher sensitivity and real-world adherence than fecal immunochemical testing (FIT) or guaiac fecal occult blood testing (FOBT). However, data on adherence and follow-up colonoscopy (FU-CY) within individual health systems are limited. This study evaluated mt-sDNA adherence, FU-CY completion, and predictors within Massachusetts General Hospital (MGH).
METHODS: We conducted a retrospective cohort study of 23,665 patients aged 45-75 years with mt-sDNA test orders in the MGH health system (June 2016-May 2023). Adherence was defined as return of a valid mt-sDNA kit. FU-CY was assessed within 12 months after a positive result. Multivariable logistic regression models identified patient- and provider-level predictors of adherence and FU-CY completion.
RESULTS: Overall adherence to mt-sDNA screening was 78.4%, with a positivity rate of 10.5%. FU-CY completion within one year was 74.2%, with 91% completed within six months. Adherence was highest among adults aged 65-75 (80.1%), Asian or Pacific Islander patients (83.0%), Medicare beneficiaries (84.0%), rural residents (82.4%), and those with prior mt-sDNA testing (89.3%). Lower adherence was observed among Black (73.6%) and Hispanic (75.7%) patients, Medicaid beneficiaries (60.0%), and orders placed by nurse practitioners/physician assistants (71.7%). Multivariable analyses identified independent predictors of adherence and FU-CY completion, including race/ethnicity, payer type, income, provider specialty, geography, and patient return history. Age and sex were significant predictors of FU-CY completion.
CONCLUSIONS: Within a large health system, mt-sDNA screening demonstrated high overall adherence and timely FU-CY completion, exceeding those historically reported for FIT/FOBT.
METHODS: We conducted a retrospective cohort study of 23,665 patients aged 45-75 years with mt-sDNA test orders in the MGH health system (June 2016-May 2023). Adherence was defined as return of a valid mt-sDNA kit. FU-CY was assessed within 12 months after a positive result. Multivariable logistic regression models identified patient- and provider-level predictors of adherence and FU-CY completion.
RESULTS: Overall adherence to mt-sDNA screening was 78.4%, with a positivity rate of 10.5%. FU-CY completion within one year was 74.2%, with 91% completed within six months. Adherence was highest among adults aged 65-75 (80.1%), Asian or Pacific Islander patients (83.0%), Medicare beneficiaries (84.0%), rural residents (82.4%), and those with prior mt-sDNA testing (89.3%). Lower adherence was observed among Black (73.6%) and Hispanic (75.7%) patients, Medicaid beneficiaries (60.0%), and orders placed by nurse practitioners/physician assistants (71.7%). Multivariable analyses identified independent predictors of adherence and FU-CY completion, including race/ethnicity, payer type, income, provider specialty, geography, and patient return history. Age and sex were significant predictors of FU-CY completion.
CONCLUSIONS: Within a large health system, mt-sDNA screening demonstrated high overall adherence and timely FU-CY completion, exceeding those historically reported for FIT/FOBT.